# A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

> **NCT06238817** · PHASE3 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 241 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Ruxolitinib Cream
- **DRUG:** Vehicle Cream

## Key facts

- **NCT ID:** NCT06238817
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-26
- **Primary completion:** 2025-05-21
- **Final completion:** 2025-10-17
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238817, "A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06238817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*